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Objective  To assess the efficacy of trigger point injection into brachialis muscle for rotator cuff disease patients 
with upper arm pain.
Methods  A prospective, randomized, and single-blinded clinical pilot trial was performed at university 
rehabilitation hospital. Twenty-one patients clinically diagnosed with rotator cuff disease suspected of having 
brachialis myofascial pain syndrome (MPS) were randomly allocated into two groups. Effect of ultrasound 
(US)-guided trigger point injection (n=11) and oral non-steroidal anti-inflammatory drug (NSAID) (n=10) was 
compared by visual analog scale (VAS).
Results  US-guided trigger point injection of brachialis muscle resulted in excellent outcome compared to the 
oral NSAID group. Mean VAS scores decreased significantly after 2 weeks of treatment compared to the baseline 
in both groups (7.3 vs. 4.5 in the injection group and 7.4 vs. 5.9 in the oral group). The decrease of the VAS score 
caused by injection (ДVAS=-2.8) was significantly larger than caused by oral NSAID (ДVAS=-1.5) (p<0.05).
Conclusion  In patients with rotator cuff disease, US-guided trigger point injection of the brachialis muscle is 
safe and effective for both diagnosis and treatment when the cause of pain is suspected to be originated from the 
muscle.
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INTRODUCTION
Rotator cuff disease including tendon tearing, prevalent 
in middle-aged individuals, is one of the most common 
causes of shoulder pain [1]. Treatments for rotator cuff 
lesions without complete tears are mainly conservative 
[2]. Among various options, subacromial injection of an-
esthetics or corticosteroids and oral non-steroidal anti-
inflammatory drugs (NSAIDs) are frequently used to treat 
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patients with persistent symptoms after rehabilitative 
therapy [3].
Myofascial pain syndrome (MPS) is considered as one 
of the possible etiologies for shoulder pain. However, 
MPS rarely occurs as a primary origin of pain [4,5]. Con-
siderable evidences suggest that MPS is caused by or re-
lated to a lesion in another soft tissue, such as rotator cuff 
disease [5,6]. Rather than being a primary generator of 
shoulder pain, MPS is accompanied with other shoulder 
lesions, such as rotator cuff disease which might overlap 
with the symptoms of shoulder lesions and aggravate the 
pain. 
Previous studies on MPS of shoulder region usually 
focused on the shoulder girdle muscles or muscles di-
rectly attached to the shoulder joint [7,8]. The trapezius, 
infraspinatus, supraspinatus, subscapularis, teres minor 
and major, deltoid, pectoralis, biceps brachii, and triceps 
muscles are all possible sources of shoulder pain in rota-
tor cuff disease [7]. However, in our clinical experience, 
a significant number of patients with rotator cuff disease 
also have the brachialis muscle-originated upper arm 
pains.
The brachialis muscle, along with biceps brachii 
muscle, is one of the main elbow flexors. Unlike biceps 
brachii, which also participates in elbow supination, the 
brachialis muscle works only in elbow flexion [9]. When 
the biceps brachii muscle is affected by rotator cuff dis-
eases, the brachialis muscle may be under more loading 
pressure and overused on elbow flexion. Therefore, com-
pared to those without shoulder rotator cuff disorders, 
patients with rotator cuff pathology may be more prone 
to the development of myofascial trigger points (MTrPs).
The common conservative treatment of rotator cuff 
disease includes physical therapy and anti-inflammatory 
therapy (either systemic or local) [10]. However, patients 
with rotator cuff disease combined with suspected MPS 
on the brachialis muscle do not respond well to conven-
tional conservative therapy that only targets rotator cuff 
tendon itself. Therefore, we hypothesized that for patients 
with rotator cuff disease who do not respond well to ther-
apy focusing on the primary shoulder lesion, the MPS of 
the brachialis muscle could be considered as an alterna-
tive pain generator, and that ultrasound (US)-guided trig-
ger point injection could be useful to diagnose the com-
bined MPS on the brachialis and to treat their pain. This 
study applied a novel US-guided trigger point injection of 
the brachialis for those patients with rotator cuff disease 
who did not respond to the subacromial injections. The 
study aimed to investigate the therapeutic effectiveness 
of US-guided trigger point injection for active MTrPs in 
the brachialis muscles. The objectives of this study were 1) 
to determine whether the newly approached US-guided 
trigger point injection of the brachialis could be effec-
tive for pain control in patients with chronic rotator cuff 
disease combined with MPS on the brachialis and 2) to 
investigate whether the brachialis was the cause of upper 
arm pain in some patients with rotator cuff disease.
MATERIALS AND METHODS
Participants
Of patients with rotator cuff disease who visited the out-
patient clinic of a university hospital between March and 
August 2013, those who met the following criteria were 
included in this study 1) were diagnosed with rotator cuff 
disease from a tendinosis to a partial-thickness tear of 
the supraspinatus based on sonographic examination 
or magnetic resonance arthrography; 2) had proximal 
upper arm pain below the shoulder joint in the affected 
shoulder side; 3) had a pain score measured by the visual 
analog scale (VAS) greater than 5 (on a numeric scale of 
0−10); 4) no weakness on resisted testing of musculoten-
dinous units of the rotator cuff; 5) had no less than 20% 
reduction in proximal upper arm pain with subacromial 
injections of local anesthetics and steroids; and 6) had 
diagnosis of MPS in the brachialis muscle. Exclusion cri-
teria were 1) presence of other obvious pathology for the 
rotator cuff pain including fracture or rheumatic diseas-
es; 2) MPS in muscles other than the brachialis muscle; 
3) neurologic shoulder/axillary pain if the patient had a 
history of posterior neck pain, 4) signs and symptoms of 
neuropathy in the affected upper limbs; 5) a history of 
other treatments for upper arm pain, such as NSAID use 
or physical therapy, within two weeks before subacromial 
injections; 6) a history of subacromial injection and/or 
trigger point injection within 3 months; 7) previous his-
tory of adverse effect of lidocaine or steroid; 8) gastroin-
testinal discomfort with NSAIDs; 9) presence of an unsta-
ble medical condition or a known uncontrolled systemic 
disease; and 10) any conditions or situations that might 
place the patient at significant risk during the study.
Diagnosis of an active MPS was based on the modified 
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criteria described by Travell and Simons [11]: 1) tender 
spots in the brachialis; 2) a typical pattern of referred 
pain is elicited when tender spots are compressed; 3) 
restricted range of motion; and 4) local twitch response 
(LTR). Tenderness could be elicited in the brachialis 
muscle by palpating the muscle between the biceps bra-
chii and triceps muscles. However, the criterion of a pal-
pable or visible LTR on snapping palpation at the most 
sensitive spot in the taut band was excluded because it 
would be impossible to observe LTRs in every case due 
to the difficulty in palpating the whole brachialis muscle. 
Instead, we elicited and assessed LTRs during US-guided 
trigger point injections [12].
This study was approved by the Institutional Review 
Board and human subjects review committee before the 
study began. Written informed consent was obtained 
from all participants after they were briefed on the pur-
pose and procedures of the study.
Study design
The present pilot study was designed as a prospective, 
randomized, and single-blinded clinical pilot trial that 
compared trigger point injection of the brachialis muscle 
with oral NSAIDs. First, patients who had painful arc 
and/or impingement sign were diagnosed with supraspi-
natus tendon disease, such as a tendinosis or a partial-
thickness tear by ultrasonography or magnetic resonance 
arthrography. Among these patients, we selected those 
with proximal arm pain on the same affected side of the 
shoulder pathology. Assuming the arm pain as ‘referred 
pain from rotator cuff disease’, we performed US-guided 
subacromial injection (a mixture of 4 mL of 0.5% lido-
caine and 1 mL of 40 mg of triamcinolone), and those 
with <20% of pain reduction 2 weeks after a subacromial 
injection were finally included in the study. These pa-
tients were randomly grouped into the oral NSAID or 
trigger point injection groups. Oral NSAID group received 
naproxen 500 mg twice a day for 2 weeks. Injection group 
received one US-guided trigger point injection into the 
brachialis muscle.
One physiatrist who was not blinded examined all pa-
tients who were referred to the clinic for eligibility. The 
investigator who evaluated the outcome measures was 
blinded to the group allocation throughout the study, al-
though the physiatrist who performed all injections and 
supervised the consumption of oral NSAIDs and the par-
ticipants were not blinded. Another trigger point injec-
tion of the brachialis or other muscles along with other 
oral analgesics and physical therapy were performed if 
pain reduction was not satisfactory after 2 weeks. Trigger 
point injections were performed at a 2-week interval. For 
the purpose of this study, we limited the study period to 2 
weeks. The comparison of the final outcome was execut-
ed 2 weeks after the first injection in the injection group, 
and 2 weeks after daily medication of NSAID in the oral 
medication group. The study design is illustrated in Fig. 1.
Ultrasound-guided trigger point injection procedure
US-guided trigger point injection methods, previously 
reported for lower back and deep pelvic muscles, have 
been modified for MTrPs in brachialis [12,13]. We per-
formed B-mode, real-time ultrasonography with sterile 
methods using an Accuvix V10 ultrasound machine (Me-
dison, Seoul, Korea) interfaced with a 5- to 12-MHz linear 
array transducer around the targeted muscle. A physiat-
Fig. 1. Design of the study. MR, magnetic resonance; 
NSAID, non-steroidal anti-inflammatory drug.
Diagnosed
with rotator cuff disease
by sonography
or MR arthrography
(n=72)
Upper arm pain
(n=29)
Within 1 week
Subacromial injection
(n=29)
Not responded to
subacromial injection
(n=24)
Compatible with
the study criteria
(n=22)
Trigger point
injection
of brachialis
(n=11)
Oral NSAID
(n=10)
Refuse (n=1)
2 weeks interval
If pain remained, other treatments
including
trigger points injections of the
brachialis or other muscles
2 weeks interval
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rist with more than 7 years of experience in musculosk-
eletal ultrasonography carried out US-guided injection 
procedures.
For ultrasound examination and injection procedures, 
the patient was positioned lying on the lateral side with 
the affected side up. The upper arm was placed tightly to 
the trunk to minimize motion during injection (Fig. 2). 
The biceps was relaxed with the forearm pronated. 
We assessed the borderline between the brachialis and 
biceps brachii from the lateral aspect of the upper arm 
and marked the maximal tender point on the skin by pal-
pating the muscle. The proximal attachment of the bra-
chialis is located around the deltoid tuberosity of the hu-
merus. To scan the brachialis muscle properly, the probe 
started from the deltoid tuberosity distally to the distal 
part of upper arm. By positioning the probe on the mark-
ing point and turning the probe to show the best view, we 
obtained the transverse image of the brachialis muscle 
(Fig. 3). In this position, the biceps brachii was located 
above the brachialis on the US image. In case of multiple 
tender spots in one muscle, US-scanning and injection 
procedures were repeated for all tender spots. Color Dop-
pler images were used to avoid neurovascular bundle. 
The Doppler setting changed at the level where vascular 
structures were optimally visualized in each subject. Un-
der US-guidance, a 23-gauge, 6.0-cm needle connected 
to a 5-mL syringe containing a mixture of 4 mL of 0.5% li-
docaine and 1 mL of 40 mg of triamcinolone was inserted 
Fig. 2. Proper positioning dur-
ing injection procedure. (A) The 
patient is laid on the lateral side 
with the affected side up, with 
the upper arm placed tightly to 
the trunk to minimize the motion 
during injection. (B) The probe is 
positioned on the maximal tender 
point to show the transverse im-
age of the brachialis muscle, and 
the needle is approached with in-
plane method.
A B
Fig. 3. Transverse ultrasound image of the brachialis 
muscle. The brachialis muscle (Br) is seen below the bi-
ceps brachii muscle (Bi). H, humerus; T, triceps.
Fig. 4. Transverse ultrasound image by the in-plane 
method. Needle passage into the target muscle (Br) is 
visualized (arrow). Bi, biceps brachii; Br, brachialis; H, 
humerus.
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into the brachialis at the MTrPs region. With the use of 
an in-plane method, the needle passing through the skin 
and adipose tissue to penetrate the muscle was visual-
ized (Fig. 4). A physiatrist observed LTRs on US while 
performing trigger point injections. Repeated needling 
was performed to different loci in that region to elicit as 
many LTRs as possible. If no LTR was observed after 8 to 
10 attempts, needling was stopped. At that point, mixture 
solution was injected. The injection site was pressed to 
ensure proper hemostasis after the procedure. No other 
therapy was allowed in each group during the study pe-
riod (2 weeks for oral NSAID or 2 weeks after injection). 
However, self-exercise and behavior corrections were al-
lowed. The patients were taught to do self-exercise com-
prising stretching exercise (repeated 10−20 times during 
a day) and to avoid the posture that might aggravate the 
symptoms.
Assessments
Patients rated pain intensity using a 10-cm horizontal 
VAS, which varied from ‘no pain (VAS 0)’ to ‘worst imag-
inable pain (VAS 10)’. VAS was assessed just before (pre-
treatment) and 2 weeks after the treatment (either trigger 
point injection or oral NSAID). ‘Success of treatment’ was 
defined as more than 50% of reduction in post-treatment 
VAS compared to pre-treatment, whereas ‘treatment fail-
ure’ was defined as <50% of post-treatment VAS reduc-
tion compared to pre-treatment. We compared the num-
ber of patients with successful treatments between each 
group.
Statistical analyses
Shapiro-Wilk test was used for all continuous variables 
for determining whether or not the distribution was nor-
mal. The general characteristics or baseline data were 
Table 1. Baseline characteristics of patients
Age (yr) Sex Side Duration (mo) LTR
Injection group
      1 62 M Right 3 No
      2 53 F Left 5 Yes
      3 74 M Right 5 Yes
      4 43 F Right 6 No
      5 49 F Right 5 No
      6 62 F Right 4 Yes
      7 55 M Right 4 No
      8 63 F Right 3 Yes
      9 57 M Left 4 No
      10 46 F Right 6 No
      11 68 M Left 7 Yes
      Mean±SD 57.5±9.5 - - 4.7±1.3 -
Medication group
      1 55 F Left 6 -
      2 71 F Right 6 -
      3 61 F Right 4 -
      4 61 M Right 3 -
      5 42 F Left 4 -
      6 50 M Right 3 -
      7 54 F Right 5 -
      8 66 M Right 6 -
      9 67 F Left 5 -
      10 54 M Left 3 -
      Mean±SD 58.1±8.8 - - 4.4±1.5 -
LTR, local twitch response; SD, standard deviation.
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compared between each group by using Mann-Whitney 
U test or chi-square test. SPSS ver. 21.0 software (IBM, 
Armonk, NY, USA) was used for the statistical analyses. 
Statistical significance was considered when p-value was 
less than 0.05.
RESULTS
Of 72 patients who were diagnosed with rotator cuff dis-
ease, 29 developed upper arm pain during the follow-up 
period, 24 were unresponsive to subacromial injections, 
and two were excluded for having clinical impression of 
MPS of muscles other than brachialis, one had clinical 
suspicion for MPS on triceps brachii, one had on both tri-
ceps brachii and brachialis muscles. Twenty-two patients 
met the final inclusion criteria, and 21 patients com-
pleted the study. Eleven patients were allocated into the 
injection group, and 10 patients were in the oral NSAID 
group (Fig. 1).
The mean age of patients included in the study was 
57.5±9.5 years for the injection group and 58.1±8.8 years 
for the oral NSAID group. LTRs were observed during US-
guided trigger point injection in 5 of 11 patients in the 
injection group. However, LTRs was not observed in the 
oral NSAID group who did not receive US-guided injec-
tion. Demographic and clinical characteristics of patients 
and assessment of treatments are summarized in Table 1. 
There was no significant difference in age, sex, or dura-
Table 2. Changes of VAS score in each treatment group
Pre-VAS Post-VAS Therapeutic response VAS difference Difference ratio
Injection group
      1 9 5 Fail -4 0.444 
      2 8 4 Success -4 0.500 
      3 7 3 Success -4 0.571 
      4 6 5 Fail -1 0.167 
      5 7 7 Fail   0 0.000 
      6 8 4 Success -4 0.500 
      7 6 3 Success -3 0.500 
      8 9 6 Fail -3 0.333 
      9 8 4 Success -4 0.500 
      10 6 3 Success -3 0.500 
      11 6 5 Fail -1 0.167 
      Mean±SD 7.3±1.2 4.5±1.3a) - -2.8±1.4b) -
Medication group
      1 7 5 Fail -2 0.286 
      2 9 7 Fail -2 0.222 
      3 8 8 Fail   0 0.000 
      4 6 6 Fail   0 0.000 
      5 6 7 Fail   1 -0.167 
      6 8 5 Fail -3 0.375 
      7 6 3 Success -3 0.500 
      8 9 7 Fail -2 0.222 
      9 7 5 Fail -2 0.286 
      10 8 6 Fail -2 0.250 
      Mean±SD 7.4±1.2 5.9±1.4a) 7.4±1.2 -1.5±1.3 -
VAS, visual analogue scale; pre-VAS, VAS at pretreatment; post-VAS; VAS after 2 weeks of treatment; SD, standard de-
viation.
a)p<0.05, comparison of pre-VAS and post-VAS. b)p<0.05, comparison of post-VAS between injection group and medi-
cation group. 
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tion of symptoms between the two groups. No significant 
difference was observed in baseline VAS either between 
the two groups (7.3 in injection group vs. 7.4 in the oral 
NSAID group) (Table 2, Fig. 5). After 2 weeks, significant 
decreases of VAS after the treatment compared to the 
baseline VAS were observed in both groups (7.3 to 4.5 
in the injection group and 7.4 to 5.9 in the oral NSAID 
group, p<0.05) (Table 2, Fig. 5). In addition, injection 
group had a significantly larger decrease of VAS score af-
ter the treatment compared to the oral NASID group (-2.8 
in injection group vs. -1.5 in oral NSAID group, p<0.05) 
(Table 2, Fig. 5). The number of patients with ‘successful 
treatment’, whose post-treatment VAS reduced more than 
50% compared to pre-treatment, was 6 of 11 (54.5%) in 
the injection group, whereas only one of 10 (10.0%) in the 
oral NSAID group had ‘successful treatment’. 
In the injection group, no patient reported any compli-
cation related to the procedure or serious adverse events 
attributable to the treatment. There were no infections or 
vascular injuries. In the oral NSAID group, two patients 
had gastric pain or discomfort related to the treatment, 
but the symptoms subsided after ceasing the medication 
at the end of the 2-week follow-up period.
DISCUSSION
This is the first report of US-guided trigger point injec-
tions of the brachialis muscle in patients with rotator cuff 
disease. Affected upper arm pain significantly decreased 
in the injection group compared to the oral NSAID group. 
Rates of treatment success were 54.5% (6 of 11) in the 
injection group and 10.0% (1 of 10) in the oral NSAID 
group.
We only included those patients who were unre-
sponsive to subacromial injection but with severe pain 
(VAS>5). Thus, even though the follow-up period was 
short (2 weeks), it could be concluded that US-guided 
trigger point injection of brachialis was effective in re-
ducing pain of rotator cuff disease combined with pain 
originating from the brachialis muscle. Moreover, we 
used the US-guided method to improve efficacy and ac-
curacy of injection. By palpating the brachialis before 
injection and precisely injecting the target muscle by US-
guided method, the chance of misdirecting to a wrong 
muscle was very small.
No previous studies have reported on pain originating 
from the brachialis muscle combined with rotator cuff 
diseases. However, in our study, 29 out of 72 patients with 
rotator cuff disease had newly developed upper arm pain 
during the follow-up period. Twenty-four patients had 
upper arm pain unresponsive to subacromial injection, 
implying that the pain was different from a referred pain 
of the primary lesion, the rotator cuff tendon. All 24 pa-
tients were clinically suspected of MPS. Among them, 23 
patients had MPS in the brachialis muscle, including one 
patient who also had MPS in the triceps brachii muscle. 
Our results suggest that the brachialis muscle is also im-
portant in the evaluation of patients with rotator cuff dis-
eases.
MTrPs often result from, or are perpetuated by, acute or 
chronic overuse of the muscle or prolonged shortening 
of the muscle [11]. However, no previous studies have ad-
dressed the reason why patients with rotator cuff disease 
are having MPS of brachialis more frequently than having 
MPS of other muscles. Moreover, MTrPs in the brachialis 
are often incorrectly assessed as bicipital tendinitis, su-
praspinatus tendinitis, and C5 or C6 nerve compression 
[14]. 
More frequent dysfunction of the brachialis muscle 
than the biceps brachii muscle in patients with rotator 
cuff diseases could be explained by different characteris-
tics of the two muscles including biomechanics. Firstly, 
the biceps brachii and brachialis are the two main elbow 
flexors. Which of these muscles plays a more important 
role in elbow flexion between biceps brachii and bra-
chialis depends on the degree of elbow flexion and po-
Fig. 5. Effect of each treatment. VAS changes significantly 
after injection and medication (*p<0.05) and VAS in in-
jection group decreases more compared to the medica-
tion group after treatment (†p<0.05). VAS, visual analogue 
scale; pre-VAS, VAS at pretreatment; post-VAS, VAS after 
2 weeks of treatment.
Pre-VAS
8
7
6
5
Post-VAS
4
Injection
Medication
*
*
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sition changes. The brachialis, not involved in forearm 
supination, accounts for the larger portion in the elbow 
flexion moment during forearm pronation, whereas the 
biceps brachii is involved more in forearm supination 
[14]. Consequently, elbow flexion can be depicted as a 
combined force of the biceps and brachialis muscles in 
different situations. The biceps brachii, also a dynamic 
shoulder stabilizer, may play a relatively smaller role in 
elbow flexion in case of rotator cuff lesion. Overloading 
pressures of elbow flexion might have directed at the bra-
chialis muscle instead [15,16]. Secondly, while the elbow 
is flexed, the main role of elbow flexion in the brachialis 
muscle is performed by the superficial head [17]. The 
proximal part of brachialis superficial head is attached to 
the humerus by partially encircling the distal tendon of 
the deltoid muscle [17,18], of which tendon and fibrous 
aponeurosis are continuous with the lateral intermuscu-
lar septum posteriorly and with the lateral aspect of the 
brachialis and deep brachial fascia anteriorly [18]. This 
tension may transfer to the brachialis muscle surround-
ing its distal end [19]. Thus, the repetitive tensions given 
to these structures may lead to MTrPs formation [11] in 
the brachialis muscle than in other muscles. Lastly, two-
joint muscles including the biceps brachii that cross two 
or more joints are located more superficially, exhibiting 
faster contraction speeds with relatively reduced force 
production [20]. Unlike the two-joint muscles, one-joint 
muscles like the brachialis have a slower contraction 
speed with increased force production. Those muscles 
that cross one joint are usually located closer to bone and 
generally more involved in postural activities. Distorted 
posture due to shoulder pain may augment tissue chang-
es in the brachialis muscle, therefore adversely affect-
ing the brachialis. Thus, position change in scapula and 
shoulder due to the rotator cuff disease may have loaded 
more pressure on the brachialis muscle. Moreover, shoul-
der pain induced by reasons other than rotator cuff dis-
ease or long-term fixation in elbow flexion position may 
also induce brachialis MPS.
Since not all patients showed LTRs during the injec-
tion procedure, the source of the pain from the brachialis 
muscle might not solely be MPS. Chronic muscle prob-
lems usually are caused by a combination of stretch-
induced muscle injury, muscle strain, and muscle spasm 
along with MPS. Therapeutic injection of steroids and 
anesthetics under US-guidance reportedly sped recovery 
and rehabilitation in professional baseball pitchers with 
internal oblique muscle strain [21]. Combined therapy 
with steroid and local anesthetic was effective for pain 
relief in three women who had adductor muscle strain 
which was not improved 3 months after transobturator 
taping [22]. Another study showed that intramuscular in-
jection of steroid was effective in patients suffering from 
chronic myofascial pain or pain from chronic muscle 
spasm in the piriformis, iliopsoas or scalenus anterior 
muscles, whereas the effect had begun to wane at 30 
days post-injection [23]. However, follow-up period of 
our study was only 2 weeks. Therefore, further studies on 
long-term effect are needed. Even if it was muscle strain, 
not MPS, that induced the pain, brachialis muscle over-
loading may induce dysfunction of brachialis muscle for 
the same reason. Considering the results of this study, 
pain originating in the musculature of the shoulder girdle 
or upper arm should also be evaluated in case of rota-
tor cuff disease. Patients with severe pain originating 
from brachialis muscle who do not respond well to oral 
NSAIDs as shown in our study should be treated with al-
ternatives including intramuscular injection. 
Limitations of our study include the small number of 
participants and the short-term period of follow-up. Not 
having any previous studies concerning the brachialis-
originated pain, we conducted a pilot study with a small 
number of patients to prove its efficacy first. The long-
term effect of intramuscular steroid injection of the bra-
chialis for patients with rotator cuff disease remains to be 
determined. There was no evidence that intramuscular 
steroid injection is the choice of treatment for the muscle 
strain or MPS. However, the purpose of this study was to 
investigate whether the brachialis was the cause of up-
per arm pain in patients with rotator cuff disease, not 
to determine the optimal treatment. The best treatment 
strategy may not be the trigger point injections with local 
anesthetics and steroid for the brachialis-originated pain, 
which needs to be studied in the future.
According to our single-blind, randomized, and con-
trolled pilot study, US-guided trigger point injection of 
the brachialis provided more significant pain relief in 
patients with rotator cuff disease when compared to oral 
NSAID medications. These findings suggest that US-
guided trigger point injections of the brachialis could 
be a safe and useful treatment for upper arm pain in pa-
tients with rotator cuff disease. Among the patients with 
rotator cuff disease, the presence of combined brachialis 
muscle-originated severe pain may extend the length of 
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overall treatment period and result in worse outcome. 
Thus, further study on the brachialis-originated pain in 
rotator cuff disease, focusing on its frequency, etiology, 
natural course, and optimal treatment, will be necessary.
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